Anti-COVID-19 Traditional Chinese Medicine Database-Reference-Cited by-同舟云学术

Anti-COVID-19 Traditional Chinese Medicine Database

Published:2022-12 Issue:6 Volume:3 Page:
ISSN:2666-7967
Container-title:Coronaviruses
language:en
Short-container-title:COVID

Author:

Zhou Jinming¹²,Chen Chao³,Zhang Rongyu¹,Wei Wancheng¹

Affiliation:

1. Department of Chemistry, Key Laboratory of the Ministry of Education for Advanced Catalysis Materials, Zhejiang Normal University, 688 Yingbin Road, Jinhua 321004, P.R. China

2. Drug Discovery & Innovation Center, College of Chemistry and Life Sciences, Zhejiang Normal University, 688 Yingbin Road, Jinhua 321004, P.R. China

3. Department of Computer, North China Institute of Science and Technology, Beijing, China

Abstract

Background: Novel coronavirus pneumonia COVID-19 has become a serious threat to human health. Traditional Chinese Medicine (TCM) has a good clinical effect in the treatment of COVID-19, with a high effective rate and a low rate of turning to the serious stage. Objective: We generated the web-accessed anti-COVID-19 TCM database to provide the anti-COVID-19 TCM information to develop effective drugs for the treatment of COVID-19. Methods: Herein, we collected these prescriptions data by querying the CNKI and Wanfang Chinese databases, the clinical guidance for COVID-19 pneumonia diagnosis and treatment, and further set up the web-accessible anti-COVID-19 TCM database. Results: Altogether, 293 different prescriptions are applied in four different COVID-19 stages of treatment, and the prevention of COVID-19 is composed of 452 TCM components. Conclusion: The database provides comprehensive information for anti-COVID TCM and thus would help to investigate novel ways to develop new anti-COVID-19 agents.

Publisher

Bentham Science Publishers Ltd.

Subject

Pharmacology (medical),Complementary and alternative medicine,Pharmaceutical Science

Reference26 articles.

1. WHO Coronavirus disease (COVID-19) pandemicAvailable from: 2022

2. Rabaan A.A.; Al-Ahmed S.H.; Haque S.; SARS-CoV-2, SARS-CoV, and MERS-COV: A comparative overview. Infez Med 2020,28(2),174-184

3. Sendi P.; Razonable R.R.; Nelson S.B.; Soriano A.; Gandhi R.T.; First-generation oral antivirals against SARS-CoV-2. Clin Microbiol Infect 2022,28(9),1230-1235

4. Wang Y.; Zhang D.; Du G.; Remdesivir in adults with severe COVID-19: A randomised, double-blind, placebo-controlled, multicentre trial. Lancet 2020,395(10236),1569-1578

5. Wen W.; Chen C.; Tang J.; Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19: A meta-analysis. Ann Med 2022,54(1),516-523